InvestorsHub Logo
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating
profile icon
Renee PremiumMember
05/06/20 5:20 PM
profile icon
thedog Free
07/08/11 9:01 AM
profile icon
ragmuff Free
12/30/10 9:23 AM
profile icon
MONEYMADE Terminated
11/29/10 9:27 AM
profile icon
thedog Free
09/23/10 2:20 AM
profile icon
originunknown Grandfathered
02/13/07 10:04 PM
profile icon
lifegear Free
02/13/07 6:20 PM
profile icon
originunknown Grandfathered
09/10/06 1:21 PM
profile icon
lifegear Free
09/10/06 12:53 PM
profile icon
originunknown Grandfathered
09/10/06 12:44 PM
profile icon
lifegear Free
09/10/06 12:41 PM
profile icon
originunknown Grandfathered
09/10/06 8:03 AM
profile icon
originunknown Grandfathered
09/10/06 7:59 AM
profile icon
lifegear Free
09/09/06 9:54 PM
profile icon
lifegear Free
09/09/06 9:51 PM
profile icon
lifegear Free
09/09/06 9:47 PM
profile icon
originunknown Grandfathered
09/09/06 9:29 PM
profile icon
lifegear Free
09/09/06 8:56 PM
profile icon
originunknown Grandfathered
09/09/06 5:37 PM

Immune Network Ltd (fka IMMFF) RSS Feed

Followers
1
Posters
7
Posts (Today)
0
Posts (Total)
23
Created
09/08/06
Type
Free
Moderator lifegear
Assistants
IMMFF -- Immune Network Ltd. Address: 2906 West Broadway Suite 365 Vancouver, BC V6K 2G8 CAN Immune Network Ltd. is a biotechnology company focused on the development of new drugs to treat major diseases predominantly involving the body's immune system. The Company's projects include Alzheimer Project AD2 and AIDS Project 1F7 and hNM01, including Hepatitis C Monoclonal Antibodies. During the year ended December 31, 2001, Immune Network suspended various projects due, in part, to fiscal constraints and for commercial reasons, although it has retained an interest in some of the projects by way of royalties in future revenues, if any. Suspended projects include Asthma Project BP1, Eczema Project BP1249, Cancer Project Viraplex, and Herpes Cold Sore Project Zorex. Website: http://www.immunenetwork.com Phone: 604-781-9094 Primary State of Incorporation: British Columbia Country of Incorporation: CANADA Officers: Allen Bain, President/CEO; Mark Glusing, COO/CFO/Secretary Outstanding Shares: 19,810,890 as of 2002-07-17 Current Capital Change: shs decreased by 1 for 10 split Ex-Date: Record Date: Pay Date: 2002-07-29 Company Notes: Formerly=Immune Network Research Ltd. until 8-00 Transfer Agent: Computershare Trust Company of Canada Inc., Vancouver, BC V6C 3B9 Immune Network's Phase 2 clinical trial results in Alzheimer’s disease. Preliminary evidence suggests that certain nano-pharmaceutical formulations may improve the potency and safety of dapsone for Alzheimer’s disease, an existing drug which is FDA-approved for other indications. Immune Network to Tackle Diabetes Market Wire, January, 2006 Immune Network Ltd. (OTC: IMMFF) advises that it has acquired an 85% interest in B.C.-based Dr Nature Health Products Inc. -- which has a breakthrough natural health product, DRN 11, that is proven clinically beneficial in the management of diabetes -- in exchange for 7.5 million Immune Network shares. Immune will now commence marketing DRN 11, the flagship product developed by Dr Nature over the past eight years. Completed regulatory filing for DRN 11 in Canada allows the Company to commence sales immediately. Sales into the U.S. and other markets will also be pursued. Pre-clinical studies have demonstrated that DRN 11 sensitizes the body's response to its own insulin making it work more efficiently (by increasing insulin binding and internalization). As a result of better utilization of insulin, muscle cell glucose uptake is increased. The significant clinical benefits against all diabetes symptoms and complications have been demonstrated through three DRN 11 clinical studies. DRN 11 is an excellent supplement compound that can be used alongside prescription medications such as the US$800 million drug Metformin. In the DRN 11 clinical studies, reductions in the range of 15-20% in blood sugar levels have complemented a noted quality of life benefit with no side effects and an overall improvement in the well being and general health of the study participants. Diabetes is the third leading cause of death in the United States with an economic cost of over $100 billion per year and affecting 18.2 million people with an estimated 15 million not yet diagnosed. Safe Harbor Statement The information in this release, other than historical information, may be considered forward-looking statements within the provisions of the Private Securities Litigation Reform Act of 1995. Projection and other forward-looking statements and management expectations regarding future events and/or financial performance of the Company -- although given in good faith -- are inherently uncertain and actual events and/or results may differ materially. For further information contact: Dr. Allen Bain 1-650-241-1888 Email Contact WEEKLY
Board Info
Posts Today
0
Posts (Total)
23
Posters
7
Moderator
Assistants
New Post